Literature DB >> 29945344

Downregulation of MiR-431 expression associated with lymph node metastasis and promotes cell invasion in papillary thyroid carcinoma.

Yang Liu1,1, Lin Li2,1, Zheng Liu1, Qingling Yuan1, Xiubo Lu1.   

Abstract

BACKGROUNDS: The purpose of this study was to investigate clinical role and functional effects of miR-431 expression in papillary thyroid carcinoma (PTC).
METHODS: Expression of miR-431 in PTC patient tissue samples and plasma samples was examined by using qRT-PCR methods. Cell migration and invasion capacity were evaluated using transwell assays. Western blot analysis was performed to detect protein expression after miR-431 overexpression in PTC cells.
RESULTS: We demonstrated that miR-431 expression was lower in PTC tissues and plasma samples compared to their corresponding controls. MiR-431 expression was particularly lower in PTC patients with lymph node (LN) metastasis. In vitro, miR-431 overexpression significantly inhibited cell migration, invasion and EMT process by upregulating E-cadherin and downregulating Vimentin expression. Additionally, wedemonstrated that miR-431 overexpression suppressed Hedgehog (Hh) signaling pathway by downregulating Gli1 expression.
CONCLUSION: Our results indicated that miR-431 could serve as a predictor for PTC patients with positive lymph node metastasis and a potential target of PTC treatment.

Entities:  

Keywords:  Papillary thyroid carcinoma; cell invasion; lymph node metastasis; miR-431

Mesh:

Substances:

Year:  2018        PMID: 29945344     DOI: 10.3233/CBM-181253

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  6 in total

Review 1.  Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.

Authors:  Georgios Geropoulos; Kyriakos Psarras; Maria Papaioannou; Dimitrios Giannis; Maria Meitanidou; Konstantinos Kapriniotis; Nikolaos Symeonidis; Efstathios T Pavlidis; Theodoros E Pavlidis; Konstantinos Sapalidis; Nada Mabrouk Ahmed; Tarek Ezzat Abdel-Aziz; Mohammad M R Eddama
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

Review 2.  MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.

Authors:  Maria Papaioannou; Angeliki G Chorti; Anthoula Chatzikyriakidou; Kleanthis Giannoulis; Sohail Bakkar; Theodosios S Papavramidis
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

3.  Association between tumor morphology and dosimetric parameters of organs at risk after intensity-modulated radiotherapy in esophagus cancer.

Authors:  Fahui Li; Yuxuan Luo; Jing Chen; Liping He; Yiying Liang; Junjie Lai; Feibao Guo
Journal:  J Appl Clin Med Phys       Date:  2022-05-30       Impact factor: 2.243

4.  MicroRNA-431 serves as a tumor inhibitor in breast cancer through targeting FGF9.

Authors:  Wei Wang; Yan Dong; Xiaoyan Li; Yingying Pan; Jiexin Du; Daotong Liu
Journal:  Oncol Lett       Date:  2019-11-20       Impact factor: 2.967

5.  Hypoxia-induced circular RNA hsa_circ_0008450 accelerates hepatocellular cancer progression via the miR-431/AKAP1 axis.

Authors:  Qiajun Du; Jie Han; Shan Gao; Shangdi Zhang; Yunyan Pan
Journal:  Oncol Lett       Date:  2020-10-29       Impact factor: 2.967

6.  FBXL19‑AS1 promotes the progression of nasopharyngeal carcinoma by acting as a competing endogenous RNA to sponge miR‑431 and upregulate PBOV1.

Authors:  Hongjun Dong; Chao Huang; Jingjing Huang
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.